Silence Therapeutics
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
12 Hammersmith Grv, London, Greater Lond...Phone Number
+44 2034576900Website
www.silence-therapeutics.comRevenue
<$5 MillionStock Symbol
SLNIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
2
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs.Explore more
Silence Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Silence Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Silence Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Silence Therapeutics has new funding data
Check if Silence Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Silence Therapeutics launches new products
Silence Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Silence Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Silence Therapeutics
Click to see if Silence Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Silence Therapeutics
Find 3 more new buyers
Compare Similar Companies to Silence Therapeutics
Compare insights from companies similar to Silence Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Silence Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Silence Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Silence Therapeutics.
Silence Therapeutics financials insights
Gather financial insights about Silence Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Private Equity
$20M
Silence Therapeutics Tech Stack
A closer look at the technologies used by Silence Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Compliance
Person-Based
Pharmaceuticals
Person-Based
Project
Pharmaceuticals, Clinical Operations
Silence Therapeutics News & Media
The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
$SCKT is today's standout mover, while biotech names $ABCL, $SLN, $NTHI are announcing major clinical milestonesSilence Therapeutics shares surge ahead of divesiran Phase 2 results call
Silence Therapeutics (NASDAQ:SLN) shares jumped 16. 2% in pre-market trading on Monday as investors positioned ahead of a conference call covering topline results from the Phase 2 SANRECO trial of divesiran, the company’s lead siRNA candidate for polycythemia vera.Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Silence Therapeutics plc (NASDAQ:SLN) is one of the most promising stocks on our list. TheFly reported on June 24 that Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of SLN with an Overweight rating and no price target. The firm highlighted […]Silence Therapeutics Announces Leadership Changes - Yahoo Finance
LONDON, December 15, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company’s President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Silence Therapeutics
Sign Up For FreeTo access detailed company insights
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for... Read More
